MedTrace Logo

Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol

NCT01008345 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-11-06

No results posted yet for this study

Summary

Randomized study. Patients with coronary artery disease equivalent will be randomized to receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day. Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment. Hypothesis is that ezetimibe will lower oxidized LDL

Conditions

Interventions

DRUG

ezetimibe

Patients will receive 10 mg/day of ezetimibe for 8 weeks

Sponsors & Collaborators

  • Pharmaline, Lebanon

    collaborator UNKNOWN

  • Hotel Dieu de France Hospital

    lead OTHER

Principal Investigators

  • rabih azar, md · Hotel Dieu

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Lebanon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01008345 on ClinicalTrials.gov